{
    "pmcid": "9801699",
    "qa_pairs": {
        "How do nanobodies designed to target the RBD of the spike protein function?": [
            "They block the interaction of the RBD with ACE2 by targeting the receptor-binding motif (RBM) directly or by sterically hindering ACE2 binding.",
            "They enhance the interaction of the RBD with ACE2 by stabilizing the receptor-binding motif (RBM).",
            "They degrade the RBD, preventing any interaction with ACE2.",
            "They facilitate the transition of the RBD to the 'up' conformation to enhance viral entry."
        ],
        "What challenge is associated with the evolving variants of SARS-CoV-2 in relation to nanobody design?": [
            "The spike protein is subject to mutations, particularly in the RBD, which can lead to immune escape.",
            "The spike protein is stable and does not mutate, making it difficult to design effective nanobodies.",
            "The spike protein mutates only in the S2 subunit, which is not targeted by nanobodies.",
            "The spike protein's mutations are irrelevant to nanobody efficacy."
        ],
        "What is one method mentioned for accelerating the development of effective nanobodies against evolving variants?": [
            "Using synthetic libraries and proteomics to speed up nanobody generation.",
            "Relying solely on traditional methods of nanobody generation.",
            "Focusing exclusively on natural nanobody sources without synthetic intervention.",
            "Avoiding the use of proteomics in nanobody development."
        ],
        "What is the composition of the SARS-CoV-2 spike protein as described in the paper?": [
            "The spike protein is a homotrimeric glycoprotein composed of S1 and S2 subunits.",
            "The spike protein is a monomeric glycoprotein composed of S1, S2, and S3 subunits.",
            "The spike protein is a dimeric glycoprotein composed of S1 and S3 subunits.",
            "The spike protein is a tetrameric glycoprotein composed of S1, S2, S3, and S4 subunits."
        ],
        "What strategy is mentioned for enhancing the neutralization potency of nanobodies against the spike protein?": [
            "Constructing multivalent nanobodies that target multiple non-overlapping epitopes on the spike protein.",
            "Using single-domain nanobodies that target a single epitope on the spike protein.",
            "Developing nanobodies that only target the S2 subunit of the spike protein.",
            "Creating nanobodies that bind to the spike protein without specificity to any particular epitope."
        ]
    }
}